ORCL - Oracle Corporation
| Previous Close | 48.33 |
| Open | 46.55 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1800 |
| Day's Range | 46.04 - 48.99 |
| 52 Week Range | 39.71 - 60.50 |
| Volume | 17,109,187 |
| Avg. Volume | 14,432,374 |
| Market Cap | 153.611B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 15.32 |
| EPS (TTM) | 3.18 |
| Earnings Date | Jun 16, 2020 - Jun 21, 2020 |
| Forward Dividend & Yield | 0.96 (1.99%) |
| Ex-Dividend Date | Apr 07, 2020 |
| 1y Target Est | 49.96 |
- Zacks
Oracle (ORCL) Expands Canada Footprint With New Cloud Region
Oracle's (ORCL) expanding global footprint and growing cloud capabilities are expected to boost client base and drive top-line growth.
- Zacks
Oracle (ORCL) Data Cloud to Aid Taboola Assess Ad Viewability
Oracle's (ORCL) Data Cloud offering, Moat, will aid Taboola to measure and verify video ad viewability.
- Investing.com
Oracle Stock Falls 3%
Investing.com - Oracle (NYSE:ORCL) Stock fell by 3.02% to trade at $48.80 by 13:19 (17:19 GMT) on Tuesday on the NYSE exchange.
- PR Newswire
Taboola Announces Collaboration with Moat to Offer 100 Percent Guaranteed Viewability or Completion for Video Advertisers
Taboola, the world's leading discovery platform, today announced a collaboration with Moat by Oracle Data Cloud, a leader in real-time attention analytics, which gives Taboola advertisers the ability to purchase video impressions on an outcome-based method, including viewable or video completion events.
- PR Newswire
Oracle Prices $20 Billion Aggregate Principal Amount of Investment Grade Notes
Oracle Corporation (NYSE: ORCL) today announced the pricing of its sale of $3,500,000,000 of 2.500% Notes due 2025 (the "2025 Notes"), $2,250,000,000 of 2.800% Notes due 2027 (the "2027 Notes"), $3,250,000,000 of 2.950% Notes due 2030 (the "2030 Notes"), $3,000,000,000 of 3.600% Notes due 2040 (the "2040 Notes"), $4,500,000,000 of 3.600% Notes due 2050 (the "2050 Notes") and $3,500,000,000 of 3.850% Notes due 2060 (the "2060 Notes"). The offering is expected to settle on April 1, 2020, subject to customary closing conditions.
- Moody's
Oracle Corporation -- Moody's downgrades Oracle's rating to A3; outlook stable
Rating Action: Moody's downgrades Oracle's rating to A3; outlook stable. Global Credit Research- 30 Mar 2020. New York, March 30, 2020-- Moody's Investors Service downgraded Oracle Corporation's senior ...
- Investing.com
Oracle Stock Rises 3%
Investing.com - Oracle (NYSE:ORCL) Stock rose by 3.05% to trade at $51.35 by 14:44 (18:44 GMT) on Monday on the NYSE exchange.
CNW GroupOracle Continues to Invest in Canada; Opens Second Canadian Cloud Region in Montreal
MONTREAL , March 30, 2020 /PRNewswire/ -- To support growing customer demand for enterprise cloud services in Canada , Oracle today announced a new Gen 2 Cloud region in Montreal. This follows the launch of its Toronto Cloud region last year, making Canada Oracle's latest country offering dual cloud regions. Now, Canadian customers and partners will have access to all Oracle Cloud services, including Oracle Autonomous Database and Oracle Autonomous Linux, as well as Oracle Cloud Applications, to unlock innovation and drive business growth.
- GuruFocus.com
Top Insider Buys Highlight for the Week of March 27
The largest Insider Buys this week were for Oracle Corp. (ORCL), Salesforce.com Inc. (CRM), AbbVie Inc. (ABBV) and FedEx Corp. (FDX) Continue reading...
- Benzinga
Notable Insider Buys In The Past Week: GM, Oracle And More
* Insider buying can be an encouraging signal for potential investors. * More insiders took advantage of fallen share prices last week. * Insiders at some real estate investment trusts were buying.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to take advantage of fallen share prices last week. Here are some of the most noteworthy insider purchases reported in the past week.Westlake Chemical Corporation (NYSE: WLK) had a 10% owner pick up 420,000 shares of this Houston-based company for $34.30 to $43.03 each. That totaled over $16.54 million. That beneficial owner is the general partner of Westlake's parent company.President Edward Shoen and a beneficial owner of AMERCO (NASDAQ: UHAL) together picked up 15,600 shares of Reno, Nevada-based company. At $273.41 per share, that came to almost $3.92 million. They and other insiders were buying shares throughout February and March.See Also: Bill Ackman Bet On Market Plummet, Turned M Into .6BA beneficial owner of Cheniere Energy Partners LP (NYSE: CQP) bought almost 156,800 shares of this Houston-based company at between $21.49 and $22.00 apiece. That totaled more than $3.42 million.A director at real estate investment trust Equity Commonwealth (NYSE: EQC) shelled out between $28.20 to $29.00 per share via trust for 100,000 shares. That totaled more than $2.88 million.A director added 30,000 Oracle Corporation (NASDAQ: ORCL) shares to his stake in the same week another director sold 90,000 of them. At prices of $45.23 to $48.66, the shares added cost more than $1.42 million. That director also purchased some Chevron shares recently.Los Angeles-based REIT Hudson Pacific Properties Inc (NYSE: HPP) saw a director return to the buy window. At prices ranging from $16.67 to $16.74, the 75,500 shares that director purchased added up to nearly $1.26 million. That same director bought 12,000 shares earlier in the month.After CEO Eric Mendelsohn and a director acquired National Health Investors Inc (NYSE: NHI) shares in previous weeks, another director joined them last week. He paid $36.16 apiece for 27,000 shares of this REIT. That cost this director more than $976,300.A HD Supply Holdings Inc (NASDAQ: HDS) director indirectly purchased over 41,100 shares of this industrial distributor at about $27.956 apiece. That totaled around $970.000. This same director bought more than 272,900 shares the prior week.The AFLAC Incorporated (NYSE: AFL) president and chief operating officer, John Crawford, acquired some shares of this supplemental insurer early last week. At about $26.29 apiece, the 25,000 shares added up to more than $657,300.And an executive at General Motors Company (NYSE: GM) picked 22,400 the automaker's shares. At $22.97 per share, that totaled more than $514,500. The transaction was pursuant to a Rule 10b5-1 trading plan.In addition, note that there was some recent insider buying at Avis Budget Group Inc. (NASDAQ: CAR), Marathon Oil Corporation (NYSE: MRO), Nike Inc (NASDAQ: NIKE) and Williams-Sonoma, Inc. (NYSE: WSM).See more from Benzinga * Benzinga's Bulls And Bears Of The Week: GM, Luckin, Slack, Tesla And More * Barron's Picks And Pans: GM, Kraft Heinz, Tesla, Under Armour And More * Barron's Picks And Pans: Intel, Johnson & Johnson, T-Mobile And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Bloomberg
Google, Oracle and Trump Put on Supreme Court Hold By Virus
(Bloomberg) -- The coronavirus pandemic has put on indefinite hold a major portion of the U.S. Supreme Court’s docket, including a multibillion-dollar clash between software giants Google and Oracle Corp. and cases that could affect President Donald Trump’s re-election chances.What was supposed to have been a drama-filled spring at the high court has instead become a season of waiting, especially for the lawyers and litigants in 20 arguments that had been scheduled for March and April. The court has postponed 11 of those cases and could do the same soon for the remaining nine.The cases include fights over congressional and grand jury subpoenas for Trump’s financial records -- clashes that need to be resolved in the court’s current term to give the president’s critics any chance of seeing the documents before the November election. Also on hold is a clash over the Electoral College for presidential elections and an $8 billion copyright dispute between Alphabet Inc.’s Google and Oracle.It’s not clear whether the justices are still hoping to resolve those cases in their current term, possibly by forgoing argument or by breaking tradition and hearing arguments by phone or online. Lawyers say they’ve received no guidance from the court on the subject, though briefing deadlines are still in force. The term normally ends in late June, although that time frame is now in doubt as well.‘Just Waiting’“As far as oral arguments go, we’re just waiting upon the court,” said Jay Sekulow, the lead lawyer for Trump in the president’s bid to block a New York grand jury subpoena for the president’s financial information. The case had been set for argument March 31.Courtroom arguments are unlikely anytime soon. Elderly people are at increased risk of dying should they contract the coronavirus, and two justices are in their 80s -- Ruth Bader Ginsburg, 87, who’s been treated in recent years for pancreatic and lung cancer, and Stephen Breyer, 81. Four others are 65 or older, including Justice Sonia Sotomayor, 65, whose type 1 diabetes puts her at additional risk.The court is moving ahead with rulings in dozens of cases that have already been argued. The justices issued four opinions earlier this week and plan to issue more on Monday. All nine justices are healthy and took part in a scheduled private conference by phone Friday, spokeswoman Kathy Arberg said.Time-Sensitive CasesThe grand jury subpoena case shows the difficulty of holding arguments in the near future. Sekulow’s adversary would be Carey Dunne, a lawyer in the Manhattan district attorney’s office whose city is at the epicenter of the Covid-19 outbreak. The White House says anyone traveling from New York should self-quarantine for 14 days.And yet the subpoena cases are also among the most time-sensitive, at least from the standpoint of the Democrats seeking the information. Lower courts required Trump’s banks and accountants to turn over the records, which could include his tax returns, but those rulings are on hold.“Delaying this case is effectively picking a side,” seven liberal groups led by Demand Justice said Wednesday. “Every day that Trump is allowed to keep his tax returns secret is a day that he has won and the public has lost.”Similarly, the court had been aiming to resolve clashes over the Electoral College, the body that will formally select the next president, before any election controversies may arise. At issue in cases scheduled for argument April 28 is whether states can stop “faithless electors” who try to cast a vote for someone other the candidate who won their state’s balloting.“We’ve gotten no indication about whether it’s going forward,” said Lawrence Lessig, a Harvard Law School professor and the lawyer for two groups of electors who say they have the right to vote as they please. But “we’re preparing as if it is.”Google and OracleOther cases could more easily be deferred until the new term opens in October. That includes Google’s appeal of a ruling that the software giant improperly used Oracle’s copyrighted programming code in the Android operating system. Oracle says it’s entitled to at least $8.8 billion in damages in the case, which had been scheduled for a March 24 argument.Google’s lawyer, Tom Goldstein, said he is preparing as if the argument will now be in April even though “it’s unlikely.” That includes taking part in “moot court” practice arguments using Google video chat, he said.Joshua Rosenkranz, Oracle’s lawyer, said he’ll put his three planned moot courts back on his schedule once the court sets a new argument date. He said he expects Chief Justice John Roberts, who argued 39 Supreme Court cases before becoming a judge, will ensure the lawyers have ample time to ramp back up.“The chief justice certainly knows how much time it takes to prepare to stand up in the Supreme Court,” he said.(Updates seventh paragraph to show opinions will be released Monday, justices are healthy)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Zacks
Is Oracle Corporation (ORCL) a Suitable Value Investor Pick Now?
Let's see if Oracle Corporation's (ORCL) stock is a good choice for value-oriented investors right now from multiple angles.
- Barrons.com
An Oracle Insider Just Made the Biggest Stock Buy in Years
Oracle shares had recently slipped to trading levels not seen since 2017, but Wick Moorman, a director at the software giant, just scooped up $1.4 million of shares. Moorman is a former CEO of both Amtrak and Norfolk Southern.
- Simply Wall St.
Trade Alert: Charles Moorman At Oracle Corporation (NYSE:ORCL), Has Just Spent US$972k Buying Shares
Those following along with Oracle Corporation (NYSE:ORCL) will no doubt be intrigued by the recent purchase of shares...
- MarketWatch
Stock buybacks expected to be ‘dismal’ in Q2, S&P says
Stock buybacks by S&P 500 companies are expected to go from being “significantly” lower in the first quarter to being “dismal” in the second quarter, as companies look to preserve cash given uncertainties over the impact of the COVID-19 pandemic, according to S&P Dow Jones Indices.
- Benzinga
Oracle Works With White House For Informal Testing Of Antimalarial Drugs For COVID-19 Effectiveness
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Oracle Corporation (NYSE: ORCL) is creating a website and mobile applications for collecting data on the treatment of novel coronavirus (COVID-19) patients with antimalarial drugs, the Washington Post reported Tuesday.What Happened Oracle is donating the project to the federal government, which will maintain oversight, according to the Post.The platforms will collect information from doctors about administering the drugs to their coronavirus patients to determine their effectiveness based on data outside of more established methods of clinical trials.The Trump administration is also exploring whether the participating doctors should receive bonus payments, the Post noted.President Donald Trump was convinced of the effectiveness of two antimalarial drugs, chloroquine and hydroxychloroquine, for the coronavirus after multiple conversations with Oracle CEO Larry Ellison, multiple officials familiar with the matter told the Post.Why It Matters Ellison is a long-term backer of Trump, and earlier this year held a fundraiser for his re-election bid, even as hundreds of employees walked out as a protest, Time reported in February.The president has publicly advocated for the use of both drugs for COVID-19 based on anecdotal evidence from China and France.Many healthcare officials, including within the Trump administration, have called for more evidence, in particular for proper clinical trials to be conducted, before the drugs are recommended for COVID-19 patients."Many of the things that you hear out there are what I had called anecdotal reports," White House Coronavirus Task Force member Anthony Fauci said on the antimalarial drugs on Saturday, as per the Post."They may be true, but they're anecdotal. So the only thing that I was saying is that if you really want definitively to know if something works, that you've got to do the kind of trial that you get, the good information."At least 18,615 people across the globe have lost their lives to the deadly virus, according to data from Johns Hopkins University. Nearly 418,000 have been infected, as the risk of further exponential spread remains.Price Action Oracle's shares closed 8.26% higher at $47.84 on Tuesday and traded another 0.23% higher in the after-hours session at $47.95.See more from Benzinga * Uber CEO Asks Trump To Provide Relief To Drivers On Its Platform Due To Pandemic * Pandemic Has Permanently Shifted Virtual Healthcare Demand, Teladoc CEO Tells Cramer As Company Stock Surge Almost 50% * Robinhood Offers Credit To Users Affected By Massive Outage(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- SmarterAnalyst
Wedbush Sees Upside For Tech Stocks, Expects Deal Frenzy to Start in Coming Months
It has become difficult for investors to assess companies amid uncertainty over the impact of the global coronavirus pandemic on the economy. In this volatile period, Wedbush Securities is seeing opportunities for companies in the technology, telecom and media sectors, and a “deal frenzy” taking off in coming months.Following conversations with insiders in the field, Wedbush analysts Daniel Ives and Strecker Backe, come back with reinforced confidence in companies focusing on cloud and remote technology, including Microsoft Corp (MSFT), Amazon Web Services (AWS), Zoom Video Communications (ZM), Citrix Systems (CTXS), and Slack Technologies. In addition, they say the shift to cyber technology is accelerating the need for security systems outside the firewall, which should go a long way to benefit Zscaler Inc (ZS) , CrowdStrike Holdings (CRWD), and CyberArk Software (CYBR) among others.Already in coming months, Wedbush analysts Ives and Backe, expect a resurgence of mergers & acquisitions as “valuations start to reach levels which can ignite a long overdue deal frenzy that could start to put a floor on the software sector as well.” (See TipRanks’ Stock Screener for technology names that could stand out at current levels)“Microsoft, Google (GOOGL), IBM (IBM), Adobe (ADBE), Salesforce (CRM), and Oracle (ORCL) are just a handful of the strategic players looking to beef up their cloud portfolios over the next year with fortress like treasure chests abound,” Ives and Backe said.Ives has an Outperform rating for Microsoft, Apple, Salesforce and Zscaler, and an Underperform rating for Slack Technologies. (See TipRanks’ Analysts’ Top Stocks)Related News: JP Morgan: These 3 Stocks Are Poised Surge by at Least 20% 5-Year Analyst Says Buy Uber Stock at Current LevelsWells Fargo Sees Compelling Value in Snap Stock More recent articles from Smarter Analyst: * Shopify withdraws FY20 guidance, citing Covid-19 uncertainty * General Electric Closes $21.4 Billion Biopharma Sale to Danaher * Sprint, T-Mobile Finally Complete Merger * For Penny Investors, Biocept Stock Makes a Good Speculative Play
- Barrons.com
Oracle Stock Is a Bargain-Priced Safe Haven, Analyst Says
J.P. Morgan’s Mark Murphy upped his rating on the stock to Overweight from Neutral, with a new target price of $55.
- TheStreet.com
Oracle Upgraded to Overweight as a `Relative Safe Haven' During Downturn
Oracle was upgraded to overweight from neutral by JPMorgan, which calls the database-software and cloud-infrastructure giant a possible "relative safe haven" during an economic downturn.
- MarketWatch
Oracle has suffered a 'lost half-decade' but now is the time to buy, says J.P. Morgan
J.P. Morgan analyst Mark Murphy upgraded shares of Oracle Corp. to overweight from neutral Friday, writing that the stock is better positioned than peers for a slowdown. "During an economic expansion phase, there is a lot of net new software spend to pursue, and Oracle has been left behind with subpar growth, as foreshadowed constantly by our survey work," he wrote. "However, the opposite is true when the economy slows, and the creative net-new software spend dries up: companies growing 70% can slow to 15% in a few quarters, and if they're starting from 30x revenues and an infinite cash flow multiple, there is essentially no floor below the stock. Oracle, in contrast, is advantaged by the stickiness of its software solutions." Murphy said that Oracle's stock has seen a "lost half-decade" with its stock "essentially flat lining since mid-June 2015 through yesterday" while the iShares Expanded Tech-Software ETF gained about 90%. "However, in our view everything that screens so 'wrong' with this stock in a bull market or economic expansion flips around if we apply the different lens that is required for the different type of environment we might be entering into," he wrote. Oracle's stock is up 1.8% in Friday trading. It's lost 18% over the past month as the S&P 500 has dropped 27%.
- Zacks
Oracle (ORCL) Soars: Stock Adds 9.7% in Session
Oracle (ORCL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
